Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
NextCure (NXTC) Stock Price & Analysis
278 Followers
NXTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $2.57
Previous Close$1.6
Volume49.30K
Average Volume (3M)305.60K
Market Cap
$44.76M
Enterprise Value-$67.33M
Total Cash (Recent Filing)$118.21M
Total Debt (Recent Filing)$6.12M
Price to Earnings (P/E)-0.7
Beta0.88
Next Earnings
Aug 01, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding27,973,289
10 Day Avg. Volume129,674
30 Day Avg. Volume305,598
Standard Deviation0.24
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.09
Forecast
1Y Price Target
$6.00Price Target Upside277.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NextCure News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNC410 has demonstrated clinical activity and a positive safety profile, offering potential in an area where CPIs are typically ineffective.
Drug DevelopmentNC410 clinical update expected to showcase a range of responses and stable disease progress in MSS/MSI-L CRC patients.
Pipeline AdvancementLNCB74, a new B7-H4 targeted ADC, shows promise with potential safety and efficacy advantages over other B7-H4 ADCs in development.
Bears Say
Drug DevelopmentDevelopment of NC762 discontinued due to limited efficacy in Phase 1b study.
Product PipelineDevelopment of NC762, a B7-H4 antibody, is being discontinued due to limited activity.
Stock ValuationAnalyst maintains a Buy Rating but is decreasing the Target to $4 given timeline changes and increased uncertainty.
---
Ownership Overview
50.08%
Insiders
7.25% Mutual Funds
14.78% Other Institutional Investors
27.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $0.98 and its highest was $2.57 in the past 12 months.
What is NextCure Inc’s market cap?
Currently, no data Available
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Aug 01, 2024 which is in 78 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on May 02, 2024. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.15.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -$0.39.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 27,973,290 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went up 2.685%.
Which hedge fund is a major shareholder of NextCure Inc?
Among the largest hedge funds holding NextCure Inc’s share is Harbourvest Partners Llc. It holds NextCure Inc’s shares valued at 11K.
---
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (277.36% Upside)
$6.00 (277.36% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.97%
12-Months-Change
Fundamentals
Return on Equity
-50.33%
Trailing 12-Months
Asset Growth
-31.37%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.
---
NXTC Stock 12 Month Forecast
Average Price Target
$6.00
▲(277.36% Upside)
Technical Analysis
Best Analysts Covering NXTC
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-24.10%
reiterated a buy rating 4 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -24.10% per trade.
---